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increase in microglial expression of CD11B and CD68. 
chGantenerumab increased pro-inflammatory cytokines 
and microglial activation, but minimal changes in CD68, 
as an indicator of phagocytosis. Injection of mC2 did not 
cause any significant inflammatory changes. Our results 
demonstrate that the ability of an antibody to clear plaques 
and induce inflammation is dependent on the epitope and 
affinity of the antibody.
Keywords Immunotherapy · Alzheimer’s disease · 
Bapineuzumab · Gantenerumab · Crenezumab · 
Inflammation
Introduction
One neuropathological hallmark of Alzheimer’s disease 
(AD) is the accumulation of amyloid β (Aβ) as extra-
cellular deposits. Data from both familial and sporadic 
forms of AD led to the hypothesis that Aβ is central to 
the pathogenesis of AD [15]. As a result there has been 
a great effort to develop drugs that will reduce the pro-
duction of Aβ or clear the deposits. One approach has 
been to immunise against Aβ, either by active immunisa-
tion against Aβ or by passive immunisation with anti-Aβ 
antibodies. Active immunisation of transgenic APP mice 
with Aβ clears plaques and reverses memory deficits 
[25], but active immunotherapy in AD patients is associ-
ated with severe inflammatory side effects [20]. Passive 
immunotherapy with monoclonal anti-Aβ antibodies also 
reduces amyloid deposition and reverses cognitive defi-
ciencies in transgenic APP mice [2, 9, 32]. Due to this 
success in experimental models, several monoclonal anti-
bodies reached clinical trials for the treatment of AD, but 
excitement towards this approach has been tempered by a 
Abstract Immunotherapy is a promising strategy for the 
treatment of Alzheimer’s disease (AD). Antibodies directed 
against Amyloid Beta (Aβ) are able to successfully clear 
plaques and reverse cognitive deficits in mouse models. 
Excitement towards this approach has been tempered by 
high profile failures in the clinic, one key issue has been 
the development of inflammatory side effects in the brain 
(ARIAs). New antibodies are entering the clinic for Alzhei-
mer’s disease; therefore, it is important to learn all we can 
from the current generation. In this study, we directly com-
pared 3 clinical candidates in the same pre-clinical model, 
with the same effector function, for their ability to clear 
plaques and induce inflammation in the brain. We produced 
murine versions of the antibodies: Bapineuzumab (3D6), 
Crenezumab (mC2) and Gantenerumab (chGantenerumab) 
with an IgG2a constant region. 18-month transgenic APP 
mice (Tg2576) were injected bilaterally into the hippocam-
pus with 2 µg of each antibody or control. After 7 days, 
the mice tissue was analysed for clearance of plaques 
and neuroinflammation by histology and biochemical 
analysis. 3D6 was the best binder to plaques and in vitro, 
whilst mC2 bound the least strongly. This translated into 
3D6 effectively clearing plaques and reducing the lev-
els of insoluble Aβ, whilst chGantenerumab and mC2 did 
not. 3D6 caused a significant increase in the levels of pro-
inflammatory cytokines IL-1β and TNFα, and an associated 
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number of high profile failures to deliver disease-modify-
ing effects. Bapineuzumab and Solanezumab both failed 
in phase III, and a phase III trial for Gantenerumab was 
abandoned after a futility analysis [12, 23]. With more 
antibodies for AD entering the clinic, including Aduca-
numab, which has shown promising effects in Phase I, it 
is imperative to learn from the first-generation antibody 
therapies to inform the development of new and improved 
clinical candidates. Bapineuzumab, a humanised IgG1, 
which recognised the N terminus of Aβ cleared plaques 
from the brains of patients in a phase II trial, however, it 
also caused oedema and micro-haemorrhage of the cere-
bral vasculature [22, 24]. These side effects limited the top 
dose in phase III trials, which potentially contributed to 
the lack of efficacy [23]. These side effects have also been 
observed with Gantenerumab (hIgG1, N terminus con-
formational epitope). Pre-clinical studies have suggested 
that side effects could be due to inflammation caused by 
Fc effector function of the therapeutic antibodies, as de-
glycosylation can prevent vascular damage in vivo [6, 13, 
29]. With this in mind, Crenezumab (hIgG4, mid-domain 
epitope) was generated with a human IgG4 constant 
region to modify Fc effector function and reduce vascular 
side effects [1].
The efficacy to clear plaques and the potential to induce 
side effects is difficult to predict due to inconsistent use of 
experimental models, epitope specificity of the antibody 
tested (N, mid or C terminus) or antibody subclass. In this 
study, we set out to compare three antibodies which have 
been in phase III clinical trials for AD: Crenezumab, Bap-
ineuzumab and Gantenerumab. Bapineuzumab is a human 
IgG1 antibody, which binds to the N terminus of Aβ (AA 
1–5), and can recognise both soluble and insoluble Aβ [23]. 
Gantenerumab is also a human IgG1 antibody which rec-
ognises a conformational epitope, making contact with the 
n terminus and the mid-domain of Aβ, reportedly binding 
more strongly to more aggregated forms compared to solu-
ble Aβ [3]. Crenezumab is a human IgG4 antibody which 
recognises a mid-domain epitope (AA 16-24), and binds to 
all forms of Aβ [1]. We produced murine versions of Cren-
ezumab (mC2), Bapineuzumab (3D6) and a mouse/human 
chimeric version of Gantenerumab (chGantenerumab) all 
with an IgG2a constant regions. We compared these anti-
bodies for their ability to clear Aβ plaques and to induce 
neuroinflammation following intracerebral injection into 
transgenic APP mice (Tg2576). Murine IgG2a subclass 
was selected as this subclass is similar to hIgG1 in terms 
of FcγR binding, and hIgG1 has been the most commonly 
used subclass for anti-Aβ immunotherapy. Here, we show 
that the affinity and epitope specificity are important for 
the efficient removal of Aβ from the CNS, but also for the 
induction of a neuroinflammatory response.
Methods
Recombinant antibody production
Antibody primary sequences for the variable domains of 
3D6, Gantenerumab and mC2 along with sequences for 
the constant regions of the mouse IgG2a heavy chain and 
mouse kappa light chain were identified from the public 
domain. Synthetic genes for the variable light chain-murine 
Kappa constant domain and variable heavy chain-mIgG2a 
constant domain were sub-cloned into the pTT5 plasmid 
for transient gene expression (Geneart). Primary structures 
of the expressed antibodies are shown in Table 1. Transfec-
tion of heavy chain and light chain expression vectors was 
performed in HEK293 6E cells using PEIpro (Polyplus) as 
a transfection reagent. The HEK293 6E expression system 
including the pTT5 vector is licensed from the National 
Research Council of Canada. Transfected cells were cul-
tured until the viability had dropped to around 50 % and 
culture media harvested by centrifugation and ultrafiltra-
tion. Antibodies were purified from clarified culture media 
by protein-G Sepharose (GE healthcare) affinity chroma-
tography followed by online desalting into PBS (Invitro-
gen) using ÄKTA express system and standard protocols 
for monoclonal antibody purification. Finally, the antibod-
ies were sterile filtered using 0.2-µm filters (Millipore) and 
kept at 4 °C. Purified antibodies were analysed for purity 
by SDS-PAGE and Bioanalyzer 2000, aggregation by 
uplc-sec (Waters), concentration by Pierce BCA kit (Ther-
moFisher) and endotoxin by endosafe PTS (all <0.025 EU/
mg, Charles River). Confirmation of the primary structure 
was done by analysing the intact mass of the heavy chain 
and light chain by RP-uplc (C4 column in 0.1 %FA; ACN 
gradient) followed by ESI–MS on a QTOF instrument 
(Waters XEVO QTOF). Multicharged spectra were pro-
cessed using the MaxEnt 1 deconvolution algorithm.
Abeta binding assay
Binding characteristics of the recombinant antibodies to Aβ 
peptide was assessed as follows: 96-well Maxisorp plates 
(Nunc, Denmark) were coated with 100 µl of 0.1 µg/ml Aβ 
1–40 peptide (America Peptide, Sunnyvale, CA) in bicarbo-
nate buffer (pH 9.6) overnight at room temperature. Plates 
were washed 5 times with PBS/0.1 % Tween and recombi-
nant anti-Aβ antibodies were serially diluted in 100 µl of 
assay buffer (PBS/1 % BSA) and incubated for 1 h at room 
temperature. After washing plates 5 times with PBS/0.1 % 
tween, antibody binding was detected by the addition of 
100 µl of using horse anti-mouse IgG conjugated to biotin 
(vector) diluted 1:200 in assay buffer. Plates were washed 
5 times before addition of 100 µl streptavidin poly-HRP 
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(1:10,000 in assay buffer, Sanquin, the Netherlands). 
Bound antibody was detected using tetramethylbenzidine 
(TMB) (Sigma) as a substrate. The substrate solution was 
made by dissolving 1 TMB tablet in 1 ml of DMSO, which 
was made up to 10 ml in phospho-citrate buffer (Sigma), 
2 µl of 30 % H2O2 (Sigma) was added to the solution 
directly before addition to the plate. 100 µl of the substrate 
solution was added to each well and allowed to develop. 
The reaction was stopped by the addition of 50 µl H2SO4 to 
each well, and absorbance was measured at 450 nm using a 
Fluostar Optima™ spectrophotometer.
Cell culture and effector function assay
The mouse macrophage cell line RAW 264.7 was cultured 
in DMEM media (Gibco) supplemented with 10 % heat 
inactivated foetal calf serum (FCS, Sigma) and 2 mM glu-
tamine (Sigma). Cells were incubated at 37 °C with 5 % 
CO2. Effector function of the recombinant antibodies was 
measured in vitro by immobilising antibodies (100 µl/well, 
5 µg/ml antibody in pH 9.6 bicarbonate buffer) to U.V. ster-
ilised 96 well ELISA plates (Nunc, Maxisorp Flat bottom). 
Unbound antibodies were removed by washing the plates 
with DMEM, plates were then blocked with cell culture 
medium containing 10 % FCS for 1 h, then 4 × 104 RAW 
cells per well were added in DMEM media containing 100 
units per ml of murine IFN-γ (Peprotech). The cells were 
cultured for 24 h and supernatant removed to measure the 
levels of TNFα by ELISA.
TNFα ELISA
TNFα levels were measured in cell culture supernatant 
using TNFα duoset™ ELISA (RnD systems), according 
the manufacturer’s instructions, with minor modification. 
Briefly, capture antibodies were coated onto maxisorp 
plates in 100 µl 0.1 M bicarbonate buffer pH 9.4 over-
night at room temperature. The plates were washed 5 times 
in PBS 0.05 % Tween. Cell culture supernatant or TNFα 
standard serially diluted in assay buffer (PBS/1 % BSA) 
was added and plates incubated for 2 h on a shaking table. 
After washing the plates, the secondary biotinylated anti-
body was added incubated for a further 2 h, before the 
addition of poly-HRP (1:10000 in PBS/1 %BSA, Sanquin, 
the Netherlands). This assay was developed and measured 
in the same way as the Aβ binding ELISA.
Animals and stereotaxic surgery
Female Tg2576 transgenic mice possessing a copy 
of human APP with the Swedish double mutate on 
(KM670/671NL) were obtained from Taconic and aged to 
18 months. Mice were kept in 12 h light–dark cycles with 
free access to food and water. Mice were randomised into 
4 groups (3D6, mC2, Gantenerumab or irrelevant mIgG2a 
control (n = 6/7 per treatment group). Mice were weighed 
and anaesthetised using sevoflurane, and secured onto a 
stereotaxic frame. A mid-sagittal incision was made expos-
ing the skull, and two burr holes were made at coordinates 
(−2.0, +1.7) and (−2.0, −1.7). A fire pulled glass capillary 
with a diameter of <50 μm (Sigma) was inserted −1.4 mm 
into the brain and 2µl of antibody (1 mg/ml) was slowly 
injected bilaterally. This method allows accurate injection 
of 2 µg of mAb with minimal mechanical damage. Sutures 
were used to close scalp and mice were left to recover in a 
thermo-regulated environment. All procedures were carried 
out in accordance with Danish law.
Tissue processing
Seven days after the injections the mice were terminally 
anaesthetised using avertin, and transcardially perfused 
with heparinised saline. The brain was removed and cut 
to two hemispheres. The left hemisphere was further dis-
sected, and a hippocampal punch was taken as described 
before [16] and frozen in isopentane over dry ice. The 
right hemisphere was mounted in optimal cutting tempera-
ture medium (OCT, Sakura Finetek, Thatcham, UK) for 
immunohistochemistry.
Immunohistochemistry
Brains were cut into 10 micron sections using a cryostat. A 
series of sections through the hippocampus was taken, and 
the site of injection was located by staining for CD11B; 
this allowed identification of the antibody-injected brain 
region to use for further immunohistochemistry. Immu-
nohistochemistry was performed as described before [27] 
using CD11B (5C6, 1:500, Serotec), CD68 (FA11, 1:500, 
Serotec) and Aβ (3D6, 1:1000, in house), FITC sheep 
anti-mouse F(ab)2 (1:500, Sigma), horse anti-mouse bioti-
nylated (1:250, Vector) and rabbit anti rat biotinylated 
(1:250, Vector).
Congo red staining
Ten micron sections were dried at 37 °C for 30 min, and 
fixed in 4 °C ethanol for 15 min before washing in three 
changes of PBS. Sections were stained for 15 min in 0.3 % 
Congo red (Sigma) in 80 % ethanol containing 0.01 % 
NaOH (Sigma). Sections were de-stained by dipping 
five times in 50 % ethanol containing 0.02 % NaOH, and 
transferred into PBS. Slides were mounted using Pro-long 
gold™ anti-fade reagent (Invitrogen) containing the coun-
terstain DAPI.
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Aβ staining in human tissue
The postmortem tissue of the AD cases was provided by 
BRAIN UK under the ethics approval obtained from the 
National Research Ethics Committee South Central Hamp-
shire B (REC reference 14/SC/0098). Formalin-fixed par-
affin-embedded brain tissue was cut into 5 µm sections on 
a microtome. Tissue was dewaxed in clearene (Surgipath), 
and rehydrated in graded alcohols. Endogenous peroxidase 
activity was quenched by incubation of tissue with 3 % 
H2O2 in methanol for 10 min, before 3 washes with tris-
buffered saline (TBS). Sections were then either incubated 
for 30 min in 80 % formic acid (Fisher) or in TBS. Sections 
were blocked for 30 min with medium containing DMEM, 
FCS BSA. Anti-Aβ antibodies were added at a concentra-
tion of 1:1000 in TBS and incubated at 4 °C overnight. Sec-
tions were then washed in 3 rinses of TBS before addition 
of biotinylated rabbit anti-mouse IgG secondary (Abcam, 
1:600) and incubated for 1 h. Bound antibody was detected 
by incubation for 30 min with ABC system (Vector), and 
washed 3 times in TBS, before developing with diamin-
obenzidine solution (DAB, Vector). Slides were dehydrated 
in graded alcohols into clearene, before mounting with per-
tex™ (Cellpath).
Quantification of immunohistochemistry
Light microscopy (DAB) and fluorescent images were 
taken on a Leica DM5000 microscope using QWIN or 
LAS software. The quantification of DAB images was per-
formed using the freeware—ImageJ. Images taken with a 
20× objective were de-convoluted using HDAB RGB val-
ues, which split images into haematoxylin and DAB chan-
nels. The DAB staining was turned into a binary image, 
and the percentage area above a marker-specific threshold 
was measured. To quantify congophilic plaques, the num-
ber of Congo red-positive deposits was counted in the hip-
pocampus. The number of plaques was then normalised to 
hippocampal area. During all quantification, the slides were 
blinded to prevent bias.
MSD measurement of Aβ and cytokines
Protein was extracted from hippocampal punches in 2 
stages, as described previously [26]. First, hippocampal 
tissue was placed in a buffer containing: 150 mM NaCL, 
25 mM TRIS 1 % triton x-100 and complete mini protease 
inhibitors (Roche). The tissue was mechanically homog-
enised and the homogenate was centrifuged at 20,000g at 
4 °C for 1 h to remove insoluble material. The supernatant 
from this fraction was used to measure pro-inflammatory 
cytokine levels and the triton soluble Aβ fraction using 
multiplex MSD technology. The pellet was re-suspended in 
70 % formic acid and incubated for 15 min to solubilise 
aggregated forms of Aβ, this solution was neutralised in 20 
volumes of pH8 TRIS, and centrifuged at 20,000g for 1 h 
and the supernatant used to measure the formic acid soluble 
Aβ fraction. Total protein levels were measured by BCA 
protein assay (Pierce), and final levels were expressed as 
pg/mg protein. The multiplex Aβ assay c-terminal antibod-
ies to capture specific Aβ peptides, and uses the antibody 
6E10 (AA 1-16) for detection.
Statistical analysis
All data are expressed as mean ± standard deviation. Sta-
tistical analysis was performed and figures created using 
Graphpad Prism software. Data were first analysed for nor-
mal distribution; normally distributed data were analysed 
by one-way ANOVA and then treatment groups were com-
pared using TUKEY post hoc analysis. Non-parametric 
data were analysed using non-parametric equivalents.
Results
Antibody characterisation
Three murine anti-Aβ antibodies: 3D6, mC2 and chGan-
tenerumab were generated recombinantly from the vari-
able domain amino acid sequences. All antibodies were 
produced with the same mouse IgG2a constant regions, to 
ensure they had the same effector function. The antibodies 
were purified and free from endotoxin and IgG aggregates 
prior to use in experiments. 3D6 and mC2 were the original 
parent antibodies of Bapineuzumab and Crenezumab.
First, the specificity and relative affinity to Aβ were 
tested by measuring binding to immobilised Aβ 1–40 
peptide. Figure 1b shows that both 3D6 and bind to 
recombinant peptide with relative high affinity (EC50 
3D6 = 0.17 pM; EC50 chGantenerumab = 0.34 pM), how-
ever, 100-fold higher levels of mC2 were required to reach 
half maximal binding (EC50 mC2 = 17.4 pM), suggest-
ing significantly lower affinity to immobilised Aβ. Anti-
bodies were then tested for binding to Aβ plaques in brain 
sections from Tg2576 mice, and to better mimic in vivo 
binding conditions tissue sections were not subjected to 
any antigen retrieval before immuno-staining. 3D6 bound 
plaques in tissue obtained from Tg2576, while no bind-
ing was observed in wild-type mice. mC2 also bound but 
fewer plaques were labelled (Fig. 1c). chGantenerumab 
labelled plaques, however, it also appeared to bind to neu-
rons in both Tg2576 and wild-type mice. All antibodies 
were produced as IgG2a isotype, using the same constant 
region, and therefore should all have the same ability to 
bind and activate FcγRs. We then tested the ability of these 
704 Acta Neuropathol (2015) 130:699–711
1 3
antibodies to bind to plaques in Tg2576 tissue sections with 
and without formic acid antigenic retrieval (Fig. 1e). For-
mic acid treatment breaks down aggregated Aβ into more 
soluble species. We found that 3D6 was able to bind to 
plaques without any antigen retrieval, but mC2 and chGan-
tenerumab could not. After formic acid treatment, mC2 
labelled plaques very well and chGantenerumab labelled 
them faintly. The conformation of Aβ in Tg2576 mice 
and human AD cases may be different, and this has previ-
ously been reported to affect target engagement of anti-Aβ 
antibodies [28]. To characterise the ability of antibodies 
to bind to Aβ from human cases, brain sections from AD 
cases were stained with and without formic acid antigenic 
retrieval (Fig. 1f). The results were comparable to Tg2576 
tissue, with 3D6 able to bind plaques without antigenic 
retrieval, but staining improved after formic acid treatment. 
The antibody mC2 bound poorly without formic acid but 
labelled plaques well after treatment. chGantenerumab 
again showed background staining, but plaque binding 
was evident after formic acid treatment. Using an FcγR 
crosslinking assay, we tested the ability of each antibody 
to activate macrophages in vitro. All IgG2a anti-Aβ anti-
bodies stimulate secretion of the cytokine TNFα compared 
to cell only controls, while mouse IgG1, a subclass which 
has lower affinity for activating FcγR, fails to induce TNFα 
secretion (Fig. 1d). In summary, 3D6 binds plaques and 
Fig. 1  In vitro binding and effector function of 3D6 chGan-
tenerumab and mC2. a Purified recombinant antibodies were sepa-
rated by reduced and non-reduced polyacrylamide electrophoresis. 
Non-reduced antibodies run as a single band, reduced antibodies 
break into heavy and light chain fragments (50, 25 kDa respectively). 
b Binding of anti-Aβ antibodies to immobilised Aβ 1–40. 3D6 and 
chGantenerumab both bind with relatively high affinity (EC50 
3D6 = 0.17 pM; EC50 chGantenerumab = 0.34 pM) mC2 bound 
with lower relative affinity (EC50 mC2 = 17.4 pM). c Binding of 
3D6, chGantenerumab and mC2 to Tg2576 (APP) and wild-type 
(WT) brain sections. d TNFα levels produced by RAW264.7 cells 
in response to immobilised Aβ antibodies or IgG1 control. Data ana-
lysed by one-way ANOVA and Tukey post hoc test, and expressed 
as mean pg/ml supernatant ± standard deviation (SD, n = 6). Data 
is representative of 3 independent experiments (****p < 0.0001). e 
Binding of antibodies to formalin-fixed tissue from Tg2576 mice, 
with and without formic acid antigenic retrieval. f Binding of anti-
bodies to human AD brain tissue, with and without formic acid anti-
gen retrieval
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recombinant Aβ 1–40 peptide with high affinity and speci-
ficity, mC2 selectively binds Aβ but with lower affinity, 
while chGantenerumab binds Aβ 1–40 peptide with high 
affinity, in situ binding indicates non-specific binding to 
neurons. All antibodies have the comparable ability to acti-
vate macrophages through FcγRs.
Clearance of Aβ
Next, we tested the ability of the anti-Aβ antibodies to clear 
Aβ in vivo by injecting 2 µg of each antibody into the hip-
pocampus of 18-month-old Tg2576 mice. Clearance of 
Aβ after intracerebral injection of antibody into Tg2576 
mice was quantified by Aβ immuno-staining. Injection of 
3D6 significantly reduced Aβ plaque load in comparison 
to chGantenerumab and mC2 (Fig. 2a, p = 0.0013 and 
p = 0.026, respectively). Due to the potential of antigenic 
masking by injected antibodies, Congo red staining was 
used to detect the clearance of congophilic deposits after 
antibody injection. 3D6 significantly reduced the number of 
Congo red-positive plaques in the hippocampus compared 
to irrelevant IgG2a and chGantenerumab injected animals 
(Fig. 2b, p = 0.0265 and p = 0.0178, respectively). The 
results were confirmed by measuring the levels Aβ38, Aβ40 
and Aβ42 in brain homogenate. Diffuse (triton soluble) Aβ 
levels were not affected 7 days post-injection. Supporting 
the decreased immuno-staining, 3D6 significantly reduced 
the amount of aggregated (formic acid soluble) Aβ38 
compared to Gantenerumab or irrelevant IgG2a injec-
tion (Fig. 3d, p = 0.0168 and p = 0.0073, respectively). 
3D6 also significantly lowered the amount of aggregated 
Aβ42 compared to irrelevant IgG2a (Fig. 3f, p = 0.041), 
and cleared aggregated Aβ40 in 50 % of mice treated with 
this antibody (Fig. 3e). chGantenerumab and mC2 did not 
induce significant changes to aggregated Aβ levels.
Inflammatory changes
Neuroinflammation is thought to be a main cause of side 
effects in patients treated with anti-Aβ antibodies, there-
fore, we compared the ability of each of the antibody to 
induce inflammation after intracerebral injection. We first 
analysed changes in microglial phenotype by immunohis-
tochemistry. Injection of 3D6 induced a significant increase 
in the expression of microglial marker CD11B, compared 
to injection with mC2 and irrelevant IgG2a (Fig. 4a–h, 
Fig. 2  Anti-Aβ immunohistochemistry and congophilic plaque 
load. a Tissue sections from Tg2576 mice injected with antibodies 
were immuno-stained for Aβ, and the percentage staining area above 
threshold was measured. Data were analysed by Kruskal–Wallis and 
Dunn’s post hoc test and expressed as mean ± SD (n = 6/7). 3D6 
significantly reduced Aβ load compared to mC2 and chGantenerumab 
(p = 0.0265 and p = 0.0013, respectively). Images taken with a ×10 
objective, scale bar 250 µm. b To test for clearance of congophilic 
plaques, brain sections from were stained with Congo red. The num-
bers of congophilic plaques were counted and normalised to hip-
pocampal area and expressed as congophilic plaques/mm2. Data were 
analysed by one-way ANOVA and Tukey post hoc test and expressed 
as mean ± SD (n = 6/7). 3D6 significantly reduced the number of 
congophilic plaques compared to irrelevant IgG2a and chGan-
tenerumab (p = 0.0265 and p = 0.0178, respectively). Images taken 
with a ×10 objective, scale bar 250 µm
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p = 0.0023 and p = 0.0017, respectively). chGantenerumab 
also induced CD11B upregulation in comparison to mC2 
and irrelevant IgG2a (p = 0.0093 and p = 0.007, respec-
tively). We have previously shown CD11B to be upregu-
lated after IgG immune complex formation in the brain 
[27], suggesting that the increase in CD11B may be due 
to FcγR binding and subsequent activation of microglia. 
To assess phagocytic activity, we analysed expression lev-
els of CD68 and detected an increased CD68 expression 
on microglia in 3D6 injected animals, but not in chGan-
tenerumab injected animals, although the increase was not 
significantly different (Fig. 4i–p, p = 0.08). Figure 4q–x 
shows staining for mouse IgG, and there is evidence of tar-
get engagement by all three of the anti-Aβ antibodies fol-
lowing intracranial injection, as plaques are positive for 
IgG. Quantification shows that chGantenerumab has sig-
nificantly higher levels of IgG than control injected animals 
(Fig. 4 q–x, p = 0.011). Unlike in vitro binding assays, 
there was no evidence of the chGantenerumab binding to 
neurons.
We showed that in vitro, all three Aβ antibodies engage 
FcγRs resulting in macrophage activation and TNFα secre-
tion. Therefore, we next investigated the neuroinflamma-
tory potential in vivo. Injection of 3D6 leads to significantly 
increased levels of pro-inflammatory cytokines TNFα and 
IL-1β compared to IgG2a control (Fig. 5a, b, p = 0.0042, 
p = 0.0262). Increased levels of KC/GRO in 3D6 injected 
animals were observed, although this did not reach signifi-
cance (Fig. 5d, p = 0.10). Injection of chGantenerumab 
also results in increased neuroinflammation, while mC2 
did not affect any cytokine levels measured. These obser-
vations suggest that high affinity IgG2a anti-Aβ antibod-
ies reduce Aβ load but this is associated with increased 
neuroinflammation.
Fig. 3  Soluble and insoluble Aβ levels measured by multiplex 
ELISA. The levels of 3 different Aβ peptides were measured by mul-
tiplex ELISA from two different fractions of brain homogenate: triton 
soluble and formic acid soluble. Aβ concentration was normalised to 
total protein levels and expressed as pg/mg total protein. a–c Levels 
of triton soluble Aβ38, Aβ40 and Aβ42, respectively. d–f Levels of 
formic acid soluble Aβ38, Aβ40 and Aβ42, respectively. With the 
exception of e, data were analysed by one-way ANOVA with Tukey 
post hoc test e was analysed by Kruskal–wallis and Dunn’s post 
hoc. Data is expressed as mean ± SD (n = 6/7). 3D6 significantly 
reduced the amount of formic acid soluble Aβ38 compared to chGan-
tenerumab and irrelevant IgG2a control (p = 0.0168 and p = 0.0073, 
respectively) and reduced levels of formic acid soluble Aβ 42 com-
pared to irrelevant IgG2a (Fig. 3f, p = 0.041)
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Fig. 4  Expression of micro-
glial activation markers after 
antibody injection. Expression 
of microglial markers CD11B 
and CD68 and IgG distribution 
in the hippocampus 7 days after 
injection of anti-Aβ antibod-
ies. a–h Representative images 
of CD11B expression. i–p 
Representative images of CD68. 
q–x Representative images 
of IgG distribution. y–ab 
No primary control sections. 
Pictures are taken with a 5× 
objective and 40× objective, 
scale bars 100 and 800 µm, 
respectively. Staining was quan-
tified as area above threshold 
of staining and analysed by 
one-way ANOVA and Tukey 
post hoc test (n = 6/7). 3D6 
induced a significant increase 
in the expression of CD11B, 
compared to injection with mC2 
and irrelevant IgG2a (Fig. 4a–h, 
p = 0.0023 and p = 0.0017, 
respectively). chGantenerumab 
also induced CD11B upregula-
tion in comparison to mC2 and 
irrelevant IgG2a (p = 0.0093 
and p = 0.007, respectively). 
chGantenerumab has sig-
nificantly higher levels of IgG 
than control injected animals 
(p = 0.011)
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Discussion
There have been a number of high profile clinical disap-
pointments for anti-Aβ immunotherapy, with Bapineu-
zumab, Solanezumab, Crenezumab and Gantenerumab 
all failing to show disease-modifying effects in clinical 
trials. Differences in: epitope and affinities for Aβ, FcγR 
affinity and the pre-clinical models used for characterisa-
tion make direct comparison difficult. Therefore, to bet-
ter understand the underlying biological mechanisms, we 
compared three highly characterised clinical candidates, 
Bapineuzumab, Gantenerumab and Crenezumab for their 
ability to clear plaques and induce neuroinflammation in 
an experimental model of Alzheimer’s disease (Tg2576). 
We generated murine, recombinant versions of Bapineu-
zumab (3D6), Crenezumab (mC2) and a mouse/human 
chimeric version of Gantenerumab (chGantenerumab). 
These antibodies were produced using the same murine 
IgG2a constant regions, and were injected intracranially 
into 18-month Tg2576 mice. The murine IgG2a constant 
region is most similar to human IgG1 and has a strong abil-
ity to activate human FcγRs and induce inflammation [4]. 
We are not aware of previous studies that directly compare 
murinised versions of Bapineuzumab, Crenezumab and 
Gantenerumab for their ability to clear plaques and induce 
inflammation.
We show that all IgG2a antibodies bind to recombinant 
immobilised peptide and plaques present in the Tg2576 
brain tissue sections, with 3D6 displaying the highest rela-
tive affinity to Aβ. The antibody chGantenerumab also 
bound with high affinity to immobilised Aβ peptide, but 
showed strong binding to neurons in cryosections of both 
transgenic and wild-type animals. mC2 was able to bind Aβ 
peptide in vitro and plaques in vivo, but the relative affin-
ity was 100-fold weaker than for 3D6. These observations 
are relevant for biological function, as 3D6, which had the 
Fig. 5  Cytokine levels following intracranial injection of anti-Aβ 
mAbs. Cytokine levels were measured in homogenate made from hip-
pocampal punches taken from Tg2576 mice injected with antibodies. 
Peptide levels were measured by multiplex ELISA and normalised 
to total protein concentration. a–f Cytokine levels in hippocampal 
punches expressed as pg.mg total protein. Injection of 3D6 leads to 
significantly increased levels of pro-inflammatory cytokines TNFα 
and IL-1β compared to IgG2a control (a p = 0.0042, b p = 0.0262). 
Data were analysed by one-way ANOVA and Tukey post hoc test 
(n = 6/7), and presented as mean ± SD
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strongest affinity for Aβ plaques in our model, was the only 
antibody to significantly reduce Aβ levels in vivo. Due to 
the potential of antigenic masking to affect the results from 
immunohistochemistry and MSD assay, we used Congo red 
staining and demonstrate that plaque numbers are reduced 
following 3D6 treatment. 3D6 injection also induced the 
activation of microglia as measured by their increase in 
CD11B expression and increased levels of the pro-inflam-
matory cytokines, IL-1β and TNFα. One of the mechanisms 
of antibody mediated plaque clearance is through activation 
of microglia FcγRs and phagocytosis [30, 31]. Crosslink-
ing of FcγRs by immune complexes leads to switching to 
an “M2b” phenotype [18], characterised by the production 
of reactive oxygen species and pro-inflammatory cytokines, 
including IL-1β and TNFα. The antibody subclass we used 
for this experiment, mouse IgG2a, is a potent inducer of 
inflammation due to its high affinity for activating receptors 
[5]. It has previously been shown that the IgG2a version of 
the anti-pyroglutamate mE8 is better at clearing plaques 
than the IgG1 version (with lower FcγR affinity), implying 
that FcγRs are involved in the clearance of plaques [10]. 
Gantenerumab did not significantly reduce the levels of 
Aβ, but detection of mouse IgG bound to plaques provides 
clear evidence for target engagement. Like 3D6, increased 
expression of CD11B was observed but minimal change in 
CD68 expression levels suggest less efficient phagocytosis 
following injection of chGantenerumab. As all antibodies 
were generated as IgG2a isotypes, this lack of phagocyto-
sis and plaque clearance is not due to lack of effector func-
tion, but rather dependent on the affinity and/or epitope. 
Bapineuzumab and Gantenerumab bind to residues in the 
N terminus of Aβ, crystal structures of Bapineuzumab in 
complex with Aβ show that it binds to amino acids 1–5 
which are in helical conformation [17]. Gantenerumab, 
in contrast, binds to a conformational epitope which also 
includes residues in the mid-domain [3]. chGantenerumab 
has a lower EC50 in our Aβ1-40 binding ELISA, when 
compared to murine 3D6 (0.34 vs 0.17 pM, respectively) 
and therefore, clearance of plaques may require more 
time—this is supported by the changes in microglial phe-
notype and cytokine production. The antibody mC2 was 
unable to clear Aβ plaques 7 days post-injection, but unlike 
chGantenerumab, this antibody did not induce any detect-
able changes in microglial phenotype or cytokine levels, 
despite having similar effector function. Immunoreactivity 
for mouse IgG strongly implies that the lack of clearance 
is due to poor plaque engagement, as IgG levels were not 
different from control IgG2a antibody. mC2 binds to a mid-
domain epitope (AA 16–24) and studies of other antibodies 
that bind this region such as, m266 (Solanezumab), suggest 
that this epitope is inaccessible when Aβ is in aggregated 
forms and this prevents antibodies like m266 from binding 
to and clearing plaques [11]. This is supported by binding 
to formic acid-treated sections, which shows that mC2 
requires the solubilisation of plaques with formic acid to 
bind. Our results demonstrate that targeting the N terminus 
of Aβ is more effective for plaque clearance. The ability of 
Crenezumab and Solanezumab to engage human Aβ in AD 
cases has previously been questioned, and cross-reactivity 
for a number of antigens has been reported [28]. We, how-
ever, found that mC2 was able to bind to Aβ in immuno-
histochemistry of human AD tissue. Antibodies that are 
unable to bind to Aβ plaque without formic acid antigen 
retrieval may not be able to engage plaques in the brains 
of AD patients. The inability to engage plaques strongly 
may prevent the removal of aggregated Aβ species from the 
brain following immunotherapy.
AD patients treated with Bapineuzumab or Gan-
tenerumab have developed dose-limiting vascular side 
effects (ARIAs), but the underlying mechanisms are not 
completely understood. There is evidence that activation 
of microglia, and/or perivascular macrophages through 
FcγRs and the subsequent neuroinflammation may be 
partly responsible for these side effects. It has been shown 
that reduced binding to FcγR can decrease the incidence of 
vascular damage in mice [6, 13, 29]. In this study, we pro-
vide further experimental evidence that antibody engage-
ment with activating FcγRs generates a pro-inflamma-
tory response in the brain, as IgG2a versions of 3D6 and 
chGantenerumab both resulted in microglial activation 
and elevated cytokine production. The clinical candidate 
Crenezumab is built on a hIgG4 backbone, which has sig-
nificantly reduced FcγR affinity compared to hIgG1. This 
was aimed to reduce the inflammatory response to immu-
notherapy and therefore reduce the associated side effects, 
and indeed ARIAs were not reported in patients treated 
with 10x the maximal dose of Bapineuzumab [1]. Our 
study provides an alternative explanation for the lack of 
side effects: the lack of plaque engagement by the antibody. 
We show that intracranial injection of an IgG2a murine ver-
sion of Crenezumab-mC2 failed to clear plaques or induce 
a pro-inflammatory response. These observations suggest 
that inflammation related to immunotherapy is not just 
dependant on the ability of the antibody to engage FcγRs 
but also on the epitope and ability of the antibody to engage 
plaques.
3D6 and mC2 are not exactly the same as the final clini-
cal candidates; Bapineuzumab and Crenezumab. This could 
mean there are slight differences in the binding affinity 
which could influence the rate of Aβ clearance and inflam-
mation; therefore, extrapolating these data should be done 
with caution. However, the clinical antibodies share the 
same epitope and are incredibly similar in sequence, and 
therefore the response is likely to be similar. Intra-cranial 
injection is a useful technique allowing rapid and cost-
efficient characterisation of the response to an antibody, 
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however, there are some limitations to this approach. To 
limit injection-mediated tissue damage, we use fine pulled 
glass capillaries to inject into the brain. However, even with 
caution any injection will cause some tissue damage, which 
may influence the subsequent immune response. Patients 
are not injected intracranially with these antibodies, and 
therefore, injecting directly into the brain is less relevant 
to the clinic than giving a systemic dose of the antibod-
ies. One factor to consider is that the localised concentra-
tion of IgG following central injection will be higher than 
after systemic treatment, which could therefore influence 
the neuroinflammatory response. To fully characterise the 
differences between these antibodies, a systemic trial is 
needed which would also allow the measurement of cogni-
tive changes. Previous studies have shown that there is vari-
ability in the response between different transgenic APP 
mouse models, in particular extensively aged mice, after 
treatment with anti-Aβ antibodies [10, 33]. Therefore, fur-
ther studies would be required to confirm the findings pre-
sented in this manuscript in different models. Furthermore, 
studies in transgenic APP mice have not always translated 
into successful clinical trials in humans; therefore, the 
response to the different anti-Aβ antibodies may differ in 
human AD patients.
We believe the results presented in the current manu-
script can inform the development of optimised clinical 
antibodies. Treatment with 3D6 is effective at clearing 
plaques, however, part of this response causes increased 
neuroinflammation. Optimised immunotherapy for AD 
ideally separates phagocytosis and neuroinflammation, 
which would allow clearance of Aβ without the induc-
tion of detrimental pro-inflammatory cytokine release. To 
achieve this, better understanding of the receptors involved 
in this processes is essential. We know that a range of dif-
ferent FcγRs is expressed in the brains of AD patients and 
mouse models [8, 14, 21], but the physiological role of 
these receptors in the brain and their relative contribution 
to neuroinflammation and plaque clearance remain poorly 
understood. 3D6 has strong target binding and a high risk 
of causing vascular side effects and inflammation, there-
fore, to minimise toxicity reduction of its effector function 
will likely be beneficial. In contrast, mC2 with lower tar-
get binding might need stronger FcγR binding to increase 
efficacy. Based on our results, we conclude that reduction 
of the effector function of Crenezumab did not have the 
expected beneficial effects, and the lack of clinical efficacy 
may be due to its lower plaque engagement. It is clear that 
we do not fully understand the role that FcγRs play in the 
CNS (see recent review [14], as there is mounting evidence 
that these receptors play a specific role in the pathology of 
dementia. In humans, six FcγRs have been identified (acti-
vatory receptors, FcγRI, IIa, IIc, IIIa, an inhibitory receptor 
FcγRIIb and a GPI-linked decoy FcγRIIIb) and the ratio of 
activatory: inhibitory expression determines the activation 
threshold of effector cells [19]. Different receptors may 
play different roles in the clearance of Aβ or in the induc-
tion of side effects. Effector function of antibodies is criti-
cal to cancer immunotherapy, and much progress has been 
made in antibody engineering to develop therapeutic anti-
bodies with improved binding to a particular receptor [7]. 
Better understanding of the role of specific FcγRs in immu-
notherapy may facilitate the modification of anti-Aβ immu-
notherapies by antibody engineering to maximise plaque 
clearance and reduce side effects.
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